Qilu Pharmaceutical Announces Results from Phase I Clinical Study for Its Novel Bispecific Antibody QLS31905 at ESMO Immuno-Oncology Congress

Posted on by

JINAN, China, Dec. 11, 2023 /PRNewswire/ — During the ESMO Immuno-Oncology Congress 2023 held in Geneva, Switzerland, from December 6th to 8th, Qilu Pharmaceutical presented the latest results of the Phase I clinical trial for QLS31905 in patients with advanced solid tumors through a…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.